AveXis, Inc. (NASDAQ:AVXS)‘s stock had its “buy” rating reissued by equities research analysts at BMO Capital Markets in a note issued to investors on Friday. They currently have a $123.00 target price on the stock. BMO Capital Markets’ price objective would indicate a potential upside of 34.19% from the stock’s current price.

Several other equities research analysts have also commented on AVXS. Jefferies Group LLC reissued a “buy” rating and set a $92.00 price target on shares of AveXis in a research note on Wednesday, April 19th. Citigroup Inc. initiated coverage on AveXis in a research note on Tuesday, May 23rd. They set a “buy” rating and a $90.00 price target on the stock. Chardan Capital set a $103.00 price target on AveXis and gave the stock a “buy” rating in a research note on Sunday, June 18th. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research note on Thursday, July 13th. Finally, Sanford C. Bernstein initiated coverage on AveXis in a research note on Thursday, July 27th. They set an “outperform” rating and a $108.00 price target on the stock. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $96.40.

AveXis (NASDAQ:AVXS) opened at 91.66 on Friday. The firm’s market cap is $2.55 billion. AveXis has a one year low of $31.55 and a one year high of $97.77. The firm’s 50 day moving average price is $85.30 and its 200-day moving average price is $73.61.

AveXis (NASDAQ:AVXS) last announced its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.06) by $1.01. During the same period last year, the firm earned ($0.68) earnings per share. Equities analysts predict that AveXis will post ($4.21) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “AveXis, Inc. (NASDAQ:AVXS) Earns Buy Rating from BMO Capital Markets” was first published by Daily Political and is the property of of Daily Political. If you are accessing this article on another domain, it was stolen and republished in violation of U.S. & international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/11/avexis-inc-nasdaqavxs-earns-buy-rating-from-bmo-capital-markets.html.

In related news, VP Sukumar Nagendran sold 1,780 shares of AveXis stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $81.88, for a total transaction of $145,746.40. Following the completion of the transaction, the vice president now directly owns 1,780 shares in the company, valued at approximately $145,746.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 5,340 shares of company stock valued at $434,872 over the last 90 days. Insiders own 18.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. BlackRock Inc. increased its position in shares of AveXis by 34.7% in the second quarter. BlackRock Inc. now owns 2,301,229 shares of the company’s stock valued at $189,069,000 after buying an additional 592,843 shares in the last quarter. Vanguard Group Inc. increased its position in shares of AveXis by 11.7% in the first quarter. Vanguard Group Inc. now owns 1,194,809 shares of the company’s stock valued at $90,841,000 after buying an additional 124,750 shares in the last quarter. Point72 Asset Management L.P. increased its position in shares of AveXis by 32.8% in the first quarter. Point72 Asset Management L.P. now owns 717,514 shares of the company’s stock valued at $54,553,000 after buying an additional 177,114 shares in the last quarter. Alliancebernstein L.P. increased its position in shares of AveXis by 4,448.8% in the second quarter. Alliancebernstein L.P. now owns 564,966 shares of the company’s stock valued at $46,418,000 after buying an additional 552,546 shares in the last quarter. Finally, Marshall Wace North America L.P. increased its position in shares of AveXis by 813.3% in the second quarter. Marshall Wace North America L.P. now owns 303,084 shares of the company’s stock valued at $24,853,000 after buying an additional 269,900 shares in the last quarter. Hedge funds and other institutional investors own 90.68% of the company’s stock.

About AveXis

AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.

Analyst Recommendations for AveXis (NASDAQ:AVXS)

Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.